The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Diversifying its portfolio to include late-phase antiviral agent
The investment in land is Rs. 19.85 crore
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
Subscribe To Our Newsletter & Stay Updated
